Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 15, 2011
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomesMalgorzata E Skaznik-Wikiel, Jamie L Lesnock, William C McBee, et al.Gynecologic Oncology|December 5, 2009
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complicationsJamie L Lesnock, Scott D Richard, Kristin K Zorn, et al.Oncotargets and Therapy|April 9, 2014
Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidityRobin A Laskey, Scott D Richard, Ashlee L Smith, et al.American Journal of Obstetrics and Gynecology|June 5, 2010
Cervical dysplasia in pregnancy: a multi-institutional evaluationAmanda N Fader, Erin K Alward, Amy Niederhauser, et al.Cell Cycle (Georgetown, Tex.)|May 1, 2015
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics studyDavid M Gau, Jamie L Lesnock, Brian L Hood, et al.Gynecologic Oncology|January 20, 2020
Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilitiesNicole B Gaulin, Jamie L Lesnock, Chunqiao Tian, et al.Brachytherapy|March 11, 2026
What is the optimal fractionation for image-based high-dose-rate brachytherapy boost in medically inoperable endometrial cancer: 4 versus 5 fractions?Abigail Groszkiewicz, Jamie L Lesnock, Paniti Sukumvanich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0Jamie L Lesnock, Sarah Temin, Sara Bouberhan, et al.Brachytherapy|January 1, 2021
Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?Adam H Richman, Ankur K Patel, Joshua L Rodríguez-López, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline UpdateStéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, et al.Pageof 3